Treatment of Childhood Acute Nonlymphoblastic Leukemia: A Review

References

• Gunz F W. Leukemia in the past. Leukemia, F W Gunz, E S Henderson. Grune & Stratton, New York 1983
   Google Scholar
• Miller D R. Hematologic malignancies: Leukemia and lymphoma. Blood Diseases of Infancy and Childhood, D R Miller, R L Baehner. St. Louis, Mosby 1990; 604–721
   Google Scholar
• Lampkin B C, Lange B, Bernstein F, et al. Biologic characteristics and treatment of acute nonlymphocytic leukemia in children. Report of the ANLL strategy group of the Childrens Cancer Study Group. Pediatr Clin North Am 1988; 35(4)743–764
   PubMed Web of Science ®Google Scholar
• Grier H E, Weinstein H J. Acute nonlymphocytic leukemia. Pediatr Clin North Am 1985; 32(3)653–668
   PubMed Web of Science ®Google Scholar
• Foon K A, Gale R P, Todd R F. Recent advances in immunologic classification of leukemia. Semin Hematol 1986; 23: 257
   PubMed Web of Science ®Google Scholar
• Champlin R, Gale R P. Acute myelogenous leukemia: Recent advances in therapy. Blood 1987; 69(6)1551–1562
   PubMed Web of Science ®Google Scholar
• Li F P, Bader J L. Epidemiology of cancer in childhood. Hematology of Infancy and Childhood, Vol 2, D G Nathan, F A Oski. Saunders, Philadelphia 1987; 918–941
   Google Scholar
• Kramer S, Meadows A T, Jarrett P, et al. Incidence of childhood cancer: Experience of a decade in a population based registry. J Natl Cancer Inst 1983; 70: 49–55
   PubMed Web of Science ®Google Scholar
• Wiernik P H. Acute leukemias. Cancer, Principles and Practice of Oncology, V De Vita, S Hellman, S A Rosenberg. Lippincott, Philadelphia 1989; 1809–1834
   Google Scholar
• Neglia J P, Robison L L. Epidemiology of the childhood acute leukemias. Pediatr Clin North Am 1988; 35(4)675–692
   PubMed Web of Science ®Google Scholar
• Miller R W. Persons with exceptionally high risk of leukemia. Cancer Res 1967; 27: 2420
   PubMed Web of Science ®Google Scholar
• Rosner F, Lee S L. Down's syndrome and acute leukemia: Myeloblasts or lymphoblastic?. Am J Med 1972; 52: 203
   PubMedGoogle Scholar
• Robison L L, Nesbit M E, Sather H N, et al. Down syndrome and acute leukemia in children: A 10-year retrospective survey from the Children Cancer Study Group. J Pediatr 1984; 105: 235–242
   PubMed Web of Science ®Google Scholar
• Weinstein H J. Congenital leukemia and the neonatal myeloproliferative disorders associated with Down's syndrome. Clin Hematol 1978; 7: 147
   PubMedGoogle Scholar
• Gunz F W, Gunz J P, Keale A MO, et al. Familial leukemia–A study of 909 families. Scand J Haematol 1975; 15: 117
   PubMedGoogle Scholar
• Sawitsky A, Bloom D, German J. Chromosomal breakage and acute leukemia and congenital telangiectatic erythema and stunded growth. Ann Intern Med 1966; 65: 487
   PubMed Web of Science ®Google Scholar
• Swift M. Fanconi's anemia in the genetics of neoplasia. Nature 1971; 230: 370
   PubMed Web of Science ®Google Scholar
• Toledano S R, Lange B J. Ataxia-telangectasia and acute lymphoblastic leukemia. Cancer 1980; 45: 1675
   PubMed Web of Science ®Google Scholar
• Gilman P A, Jackson D P, Guild H G. Congenitalagranulocytosis. Prolonged survival and terminal acute leukemia. Blood 1970; 36: 576
   PubMed Web of Science ®Google Scholar
• Woods W G, Roloff J S, Lukens J N, et al. The occurrence of leukemia in patients with the Schwachmann syndrome. J Pediatr 1981; 99(3)425
   PubMed Web of Science ®Google Scholar
• Wasser J, Yolken R H, Miller D R, et al. Congenital hypoplastic anemia (Diamond-Blackfan syndrome) terminating in acute myeloblasts- leukemia. Blood 1978; 51: 991
   PubMed Web of Science ®Google Scholar
• Reich S D, Weirnick P H. Von Recklinghausen neurofibromatosis and acute leukemia. Am J Dis Child 1976; 130: 888
   PubMedGoogle Scholar
• Robison L L, Buckley J, Daigle A, et al. Childhood acute nonlymphocytic leukemia (ANLL): Association with in vitro marijuana exposure (abstract). Proc Am Soc Clin Oncol 1987; 6: 231
   Google Scholar
• Tucker M A, Meadows A T, Boice J D, et al. Secondary leukemia after alkylating agents for childhood cancer (abstract). Proc Am Soc Clin Oncol 1984; 3: 85
   Google Scholar
• Kaldor J M, Day N E, Clarke E A, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322(1)7–13
   PubMed Web of Science ®Google Scholar
• Coleman C N, Williams C J, Flint A, et al. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 1977; 297: 1249–1252
   PubMed Web of Science ®Google Scholar
• Fiaklow P J, Singer J W, Raskind W H, et al. Clonal development, stem cell differentiation and clinical remission in acute nonlymphocytic leukemia. N Engl J Med 1987; 317: 468
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 626–629
   PubMedGoogle Scholar
• Bennett J M, Catovsky D, Daniel M, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 460–462
   PubMed Web of Science ®Google Scholar
• Griffin J D, Mayer R J, Weinstein H J, et al. Surface marker analysis of acute myeloblastic leukemia. Identification of differentiation associated phenotypes. Blood 1983; 62: 557
   PubMed Web of Science ®Google Scholar
• Sandberg A A. The chromosomes in human leukemia. Semin He-matol 1986; 23(3)201–217
   PubMed Web of Science ®Google Scholar
• Yunis J J, Brunning R D, Howe R B, et al. High resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. N Engl J Med 1984; 311(13)812–818
   PubMed Web of Science ®Google Scholar
• Woods W G, Nesbit M E, Buckley J, et al. Correlation of chromosome abnormalities with patient characteristics, histologic subtypes and induction success in children with acute nonlymphocytic leukemia. J Clin Oncol 1985; 3: 3–11
   PubMed Web of Science ®Google Scholar
• Schaison G, Baranger L, Baruchel A, et al. Pure monosomy 7 in children. A report of 14 cases. Blood 1990; 76(10)316, (a)
   Google Scholar
• Wiernick P, Serpick A P. Granulocytic sarcoma (chloroma). Blood 1970; 35: 361
   PubMed Web of Science ®Google Scholar
• Eshghabadi M, Shojania A M, Carr I. Isolated granulocytic sarcoma: Report of a case and review of the literature. J Clin Oncol 1986; 4(6)912–917
   PubMed Web of Science ®Google Scholar
• Meyer R J, Ferreria P PC, Cuttner J, et al. Central nervous system involvement at presentation in acute granulocytic leukemia. Am J Med 1980; 68: 691
   PubMed Web of Science ®Google Scholar
• Bunin N J, Pui C H. Differing complications of hyperleucocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol 1985; 3(12)1590–1595
   PubMed Web of Science ®Google Scholar
• Grier H. E., Gelber R D, Camitta B M, et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987; 5(7)1026–1032
   PubMed Web of Science ®Google Scholar
• van Wering E R, Kamps W A. Acute leukemia in infants. A unique pattern of acute nonlymphocytic leukemia. Am J Pediatr Hematol Oncol 1986; 8(3)220–224
   PubMedGoogle Scholar
• Schaison G, Daniel M T, Berger R, et al. De novo acute mega-karyoblastic leukemia in children, a study of 22 cases (abstract). Blood 1990; 76(10)316a, Suppl l
   Google Scholar
• Oliveira M SP, Ribeiro R C, Silva M LM, et al. Platelet associated membrane markers and myeloperoxidase expression distinguish megakaryoblastic leukemia in children (abstract). Blood 1990; 76(10)306a, Suppl l
   Google Scholar
• Kojima S, Matsuyama T, Sato T, et al. Down's syndrome and acute leukemia in children: An analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood 1990; 76(11)2348–2353
   PubMed Web of Science ®Google Scholar
• Ravinranath Y, Abella E, Krisher J. Acute myeloid leukemia (AML) in Down's syndrome: A highly curable disease (abstract). Blood 1990; 76(10)3lla, Suppl l
   Google Scholar
• Rubin C M, O'Leary M O, Koch P A, et al. Bone marrow transplantation for children with acute leukemia and Down syndrome. Pediatrics 1984; 78(4)688–691
   Web of Science ®Google Scholar
• Arenson E B, Forde M D. Bone marrow transplantation for acute leukemia and Down syndrome: Report of a successful case and results of a national survey. J Pediatr 1989; 114: 69–72
   PubMed Web of Science ®Google Scholar
• Creutzig U, Ritter J, Riehm H, et al. Improved treatment results in childhood acute myelogenous leukemia: A report of the ger-man cooperative study AML-BFM-78. Blood 1985; 65(2)298–304
   PubMed Web of Science ®Google Scholar
• Creutzig U, Ritter J, Schellong G, et al. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83, as compared with study AML-BFM-78. Blood 1990; 75(10)1932–1940
   PubMed Web of Science ®Google Scholar
• Evans D IK, Morris-Jones P H, Morley C J. Treatment of acute myeloid leukemia of childhood with cytosine arabinoside, daunomycin, prednisolone and mercaptopurine or thioguanine. Cancer 1975; 36: 1547
   PubMed Web of Science ®Google Scholar
• Haghbin M, Murphy M L, Tan C TC. Treatment of acute nonlymphocytic leukemia in children with a multiple drug protocol. Cancer 1977; 40: 1417
   PubMed Web of Science ®Google Scholar
• Steuber C P, Culbert S J, Ravindranath Y, et al. Therapy of childhood acute nonlymphocytic leukemia: The pediatric oncology group experience 1977–1988. Haematol Blood Transfus 1990; 33: 199–209
   Google Scholar
• Steuber C P, Civin C, Krischer J, et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: Results of a Pediatric Oncology Group study. J Clin Oncol 1991; 9(2)247–258
   PubMed Web of Science ®Google Scholar
• Ravindranath Y, Steuber C P, Krischer J, et al. High dose cytara-bine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group study. J Clin Oncol 1991; 9(4)572–580
   PubMed Web of Science ®Google Scholar
• Amadori S, Ceci A, Comelli E, et al. Therapy of childhood acute myelogenous leukemia: An update of the AIEOP/LAM 8204 study. Haematol Blood Transfus 1990; 33: 223–225
   Google Scholar
• Buckley J D, Lampkin B C, Nesbit M E, et al. Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunomycin: A report from the Childrens Cancer Study Group. Med Pediatr Oncol 1989; 17: 382–390
   PubMedGoogle Scholar
• Buckley J D, Chard R L, Baehner R L, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group. Cancer 1989; 63(8)1457–1465
   PubMed Web of Science ®Google Scholar
• Woods W G, Ruymann F B, Lampkin B C, et al. The role of timing of high dose Cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute nonlymphocytic leukemia. Cancer 1990; 66(6)1106–1113
   PubMed Web of Science ®Google Scholar
• Lampkin B, Wells R, Woods W, et al. Preliminary results: Transplantation (BMT) vs intensification chemotherapy and maintenance chemotherapy vs no maintenance in childhood acute nonlymphocytic leukemia (abstract). Proc Am Soc Clin Oncol 1990; 9: 834
   Google Scholar
• Woods W G, Lange B J, Kobrinsky N, et al. Intensively timed induction therapy followed by autologous (auto) or allogeneic (alio) bone marrow transplantation (BMT) for children with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS): A CCSG pilot study (abstract). Proc Am Soc Clin Oncol 1991; 10: 234
   Google Scholar
• Ritter J, Creutzig U, Schellong G. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the german childhood AML studies BFM-78 and BFM-83. Haematol Blood Transfus 1990; 33: 185–192
   PubMedGoogle Scholar
• Klingebiel T, Ritter J, Scellong G, et al. Roles and perspectives of BMT in AML: The BFM experience. Bone Marrow Transplant 1991; 7(3)66–70
   PubMedGoogle Scholar
• Goldberg M A, Ginsburg D, Mayer R J, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 1987; 69(1)187–191
   PubMed Web of Science ®Google Scholar
• Schwartz B S, Williams E C, Conlan M G. Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2 plasmin inhibitor deficiency. Ann Intern Med 1986; 105: 873–877
   PubMed Web of Science ®Google Scholar
• Drapkin R L, Gee T S, Dowling M D, et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484
   PubMed Web of Science ®Google Scholar
• Gralnick H R, Bagley J, Abrell E. Heparin treatment for the hemorrhagic diathesis of acute promyelocytic leukemia. Am J Med 1972; 52: 167
   PubMed Web of Science ®Google Scholar
• Sanders J E, Thomas E D, Buckner C D, et al. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: An update. Blood 1985; 66(2)460–462
   PubMed Web of Science ®Google Scholar
• Brochstein J A, Kernan N A, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med 1987; 317(26)1618–1624
   PubMed Web of Science ®Google Scholar
• McGlave P B, Haake R J, Bostrom B C, et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 1988; 72(5)1512–1517
   PubMed Web of Science ®Google Scholar
• Dini G, Abla O, Uderzo C, et al. Allogeneic bone marrow transplantation in children with ANLL: Italian experience. Bone Marrow Transplant 1991; 7(3)76–77
   PubMedGoogle Scholar
• Bortin M M, Horowitz M M. Current Status of bone marrow transplantation. Clinical Transplants, P Terasaki. UCLA Tissue Typing Laboratory, Los Angeles 1989; 93–104
   Google Scholar
• International Bone Marrow Transplant Registry. Transplant or chemotherapy in acute myelogenous leukemia?. Lancet 1989; 1: 1119–1122, May 20
   PubMed Web of Science ®Google Scholar
• Geller R B, Saral R, Piantadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73(8)2209–2218
   PubMed Web of Science ®Google Scholar
• Copelan E A, Biggs J C, Thompson J M, et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy 2. Blood 1991; 78(3)838–843
   PubMed Web of Science ®Google Scholar
• Forman A J, Krance R A, O'Donnell, et al. Bone marrow transplantation for acute nonlymphoblastic leukemia during first complete remission. Transplant 1987; 43(5)650–653
   PubMed Web of Science ®Google Scholar
• Meloni G, Vignetti M, Andrizzi C, et al. ABMT for children with AML: Italian experience. Bone Marrow Transplant 1991; 7(3)71–74
   PubMedGoogle Scholar
• Herve P, Labopin M, Plouvier E, et al. Autologous bone marrow transplantation for childhood acute myeloid leukemia–A European Survey. Bone Marrow Transplant 1991; 8(Suppl 1)76–79
   PubMedGoogle Scholar
• Gorin N C, Labopin M, Gorin E BMT. European survey on 1688 autografts for consolidation of acute leukemia: Further evidence that marrow purging with mafosfamide is effective in acute myelocytic leukemia (AML). Blood 1990; 76(Suppl l)542a
   Google Scholar
• Gorin N C, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A european survey of the role of marrow purging. Blood 1990; 75: 1606–1614
   PubMed Web of Science ®Google Scholar
• Mangoni L, Carlo-Stella C, Carella A M, et al. Autologous bone marrow transplantation (ABMT) in ANLL in first remission: Chemical and immunological properties of mafosfamide for minimal residual disease control. Blood 1990; 76(Suppl l)551a
   Google Scholar
• Tan C, Steinherz P, Meyers P, et al. Idarubicin in combination with high dose cytosine arabinoside in patients with acute leukemia in relapse. Proc Ann Meeting Am Assoc Cancer Res 1990; 3LA: 1133
   Google Scholar
• Berman E, Raymond G, Gee T S, et al. Results of a randomized trial comparing idarubicin/cytosine arabinoside (ara-C) with daunomycin/ara-C in adult patients with untreated acute nonlymphocytic leukemia. Blood 1988; 72(5)189a, Suppl l
   Google Scholar
• Liang D C, Jiang J C. Epirubicin and cytosine arbinoside for the induction therapy of childhood acute non-lymphocytic leukemia. Blood 1990; 76(10)295a, Suppl l
   Google Scholar
• Ho A D, Brado B, Haas R, et al. Etoposide in acute leukemia. Past experience and future perspectives. Cancer 1991; 67(Suppl 1)281–284
   PubMed Web of Science ®Google Scholar
• Hakami N, Look A T, Steuber P C, et al. Combined etoposide and 5-azacytidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1987; 5(7)1022–2025
   PubMed Web of Science ®Google Scholar
• Warrell R P, Frankel S R, Miller W H, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324(20)1385–1393
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel M T, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76(9)1704–1709
   PubMed Web of Science ®Google Scholar
• Chomienne C, Ballerini P, Balitrand N, et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: Structure-function relationship. Blood 1990; 76(9)1710–1717
   PubMed Web of Science ®Google Scholar
• Scheinberg D A, Lovett D, Divgi C R, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; 9(3)478–490
   PubMed Web of Science ®Google Scholar
• Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700–711
   PubMed Web of Science ®Google Scholar
• Lacombe F, Dumain P, Puntous M, et al. Clinical and biological results in AML patients treated with GM-CSF and intensive chemotherapy. Blood 1990; 76(Suppl l)292a
   Google Scholar
• Blaise D, Stoppa A M, Brandelys M, et al. Treatment of relapsed acute myeloid leukemia (AML) with systemic recombinant in-terleukin 2 (rIL2). Blood 1990; 76(Suppl l)255a
   Google Scholar
• Foa R, Meloni G, Tosti S, et al. Treatment of acute myeloid leukemia patients with recombinant interleukin 2: A pilot study. Br J Haematol 1991; 77: 491–496
   PubMed Web of Science ®Google Scholar
• Ohrling M, Juliusson G, Lenkei R. Up-regulation of the interleukin-2 receptor (IL-2R) during treatment with recombinant interleukin-2 in human acute myeloblasts leukemia (AML) in vivo. Blood 1990; 76(Suppl l)306a
   Google Scholar
• Lee F J, Van Echo D A, Egorin M J, et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult nonlymphocytic leukemia. Blood 1986; 67: 182
   PubMed Web of Science ®Google Scholar